CRESCENT BIOPHARMA INC · Data as of 2026-09-08
Jul 2026–Aug 2027
Additionally, Kelun recently initiated a Phase 2 clinical study in China of its trophoblast cell-surface antigen 2 (TROP2)-directed ADC sacituzumab tirumotecan ("sac-TMT") in combination with CR-001 to evaluate the safety, tolerability, and efficacy of patients with non-small cell lung cancer ("NSCLC"), with initial data anticipated in mid-2027 (second or third quarter).Source filing
Q1 2027
In the first quarter of 2027, we anticipate sharing meaningful data on CR-001's clinical profile, including initial safety, pharmacokinetics ("PK") and early anti-tumor activity from dose escalation and backfill cohorts in first-line and previously treated patients.Source filing
Late 2027
A Phase 1/2 combination trial of CR-003 and CR-001 is expected to initiate in the first half of 2027, with initial data anticipated by year-end 2027.Source filing